NCT00533910View on ClinicalTrials.gov

Rifaximin in Minimal Hepatic Encephalopathy

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

May 31, 2010

Conditions
Hepatic Encephalopathy
Interventions
DRUG

Rifaximin

550mg BID rifaximin for 8 weeks

DRUG

placebo

same as the experimental arm

Trial Locations (1)

23249

Hunter Holmes McGuire VA Medical Center, Richmond

All Listed Sponsors
collaborator

Bausch Health Americas, Inc.

INDUSTRY

lead

Hunter Holmes Mcguire Veteran Affairs Medical Center

FED

NCT00533910 - Rifaximin in Minimal Hepatic Encephalopathy | Biotech Hunter | Biotech Hunter